Current studies into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are revealing encouraging outcomes in treating excess mass and type second-type diabetes. Animal information suggest a novel mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/